Dr. Mittendorf Discusses Immunotherapy Efforts in Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, Robert and Karen Hale Distinguished Chair in Surgical Oncology, director, Breast Immuno-Oncology Program, Director of Research, Breast Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, discusses immunotherapy efforts in breast cancer.

Mittendorf says that there is some interesting neoantigen work being done at Dana-Farber Cancer Institute, specifically antigen discovery. The goal of antigen discovery is to identify targets for vaccination.

Another area of interest is evaluating the impact of current standard therapies for breast cancer on the immune microenvironment. This is work that Mittendorf plans to continue with the help of collaborators and new technology. Research will focus on both lymphoid and myeloid cells, Mittendorf says.